In 822 children aged 6–18 months at high risk of asthma, 24 months of oral bacterial lysate OM-85 did not delay first wheezing lower respiratory illness vs placebo over 36 months off drug (21% vs 18%; HR 1·16, 95% CI 0·82–1·64).
RCTn = 822
Morgan et al. Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial